

April 4, 2019

Division of Dockets Management Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD 20852

To the Division of Dockets Management:

We hereby withdraw our petition to the Food and Drugs Administration to require a moratorium on new opioid approvals, currently posted at Docket No. FDA-2019-P-1364-0001 at <a href="https://www.regulations.gov">www.regulations.gov</a>.

We will be submitting a revised petition requesting the same agency actions that includes the certification statement required under section 505(q) of the Food, Drug, and Cosmetic Act.

Thank you for your attention to this matter.

Sincerely,

Sidney Wolfe, M.D.

Founder, Senior Adviser

Public Citizen's Health Research Group

Raeford E. Brown, Jr, M.D., FAAP

Magnel Rown, M.D., FAAP

Professor of Anesthesiology and Pediatrics

The University of Kentucky/Kentucky Children's Hospital

Chair, FDA Anesthetic and Analgesic Drug Products Advisory Committee